FDA approves first treatment Dupixent (Dupilumab) for chronic rhinosinusitis with nasal polyps

It’s only fair to share… The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps. …

FDA approves first treatment Soliris (eculizumab) for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system

It’s only fair to share… The U.S. Food and Drug Administration today approved Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is an autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal …

Octamoxin, октамоксин , أوكتاموكسين , 奥他莫辛 ,

It’s only fair to share… Octamoxin Molecular FormulaC8H20N2 Average mass144.258 Da Octan-2-ylhydrazine Octomoxine UNII:0HXY3M6S54 UNII:2NJ66SLA5C UNII:895PL98ZMY 4684-87-1 [RN] 65500-65-4 [RN] 895PL98ZMY 0HXY3M6S54 1776 2-Hydrazinooctane 2NJ66SLA5C CAS Registry Number: 4684-87-1 CAS Name: (1-Methylheptyl)hydrazine Additional Names: 2-hydrazinooctane; octomoxine Trademarks: Ximaol Molecular Formula: C8H20N2 Molecular Weight: 144.26 Percent Composition: C 66.61%, H 13.97%, N 19.42% Literature References: Monoamine oxidase inhibitor. Prepd by condensation of methyl hexyl ketone and …

CK-101

It’s only fair to share…   CK-101, RX-518 CAS 1660963-42-7 MF C29 H28 F2 N6 O2 MW 530.57 2-Propenamide, N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-8-quinazolinyl]phenyl]- N-[3-[2-[[2,3-Difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide EGFR-IN-3 UNII-708TLB8J3Y 708TLB8J3Y AK543910 Suzhou NeuPharma (Originator) Checkpoint Therapeutics Non-Small Cell Lung Cancer Therapy Solid Tumors Therapy PHASE 2 Checkpoint Therapeutics, Cancer, lung (non-small cell) (NSCLC), solid tumour RX518(CK-101) is an orally available third-generation and selective inhibitor of certain epidermal growth factor …

Labetalol Hydrochloride, ラベタロール ,

It’s only fair to share… Labetalol ラベタロール; Molecular FormulaC19H24N2O3 Average mass328.405 Da Labetalol hydrochloride, AH-5158A, Sch-15719W, Amipress, Trandate, Normodyne Labetalol was granted FDA approval on 1 August 1984 Presolol; (RS)-2-Hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; 5-[1-Hydroxy-2-[(1-methyl-3-phenyl propyl)amino]ethyl]salicylamide A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. 253-258-3 [EINECS] 2-Hydroxy-5-{1-hydroxy-2-[(4-phenyl-2-butanyl)amino]ethyl}benzamide [ACD/IUPAC Name] 2-Hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide 36894-69-6 [RN] Benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)- Benzamide, …

FDA approves new add-on drug Nourianz (istradefylline) to treat off episodes in adults with Parkinson’s disease

It’s only fair to share… READ AT https://newdrugapprovals.org/2016/04/25/istradefylline/ FDA approves new add-on drug  Nourianz (istradefylline)  to treat off episodes in adults with Parkinson’s disease The U.S. Food and Drug Administration today approved Nourianz (istradefylline) tablets as an add-on treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes. An “off” episode is a …

FDA approves treatment Inrebic (fedratinib) for patients with rare bone marrow disorder

It’s only fair to share… FDA approves treatment Inrebic (fedratinib) for patients with rare bone marrow disorder Today, the U.S. Food and Drug Administration approved Inrebic (fedratinib) capsules to treat adult patients with certain types of myelofibrosis. “Prior to today, there was one FDA-approved drug to treat patients with myelofibrosis, a rare bone marrow disorder. …

FDA approves third oncology drug Rozlytrek (entrectinib) that targets a key genetic driver of cancer, rather than a specific type of tumor

It’s only fair to share… FDA approves third oncology drug Rozlytrek (entrectinib) that targets a key genetic driver of cancer, rather than a specific type of tumor  FDA also approves drug for second indication in a type of lung cancer The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib), a treatment for …

FDA approves new antibiotic Xenleta (lefamulin) to treat community-acquired bacterial pneumonia

It’s only fair to share… FDA approves new antibiotic  Xenleta (lefamulin) to treat community-acquired bacterial pneumonia The U.S. Food and Drug Administration today approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. “This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease,” said Ed Cox, M.D., …

AK-3280

It’s only fair to share… AK-3280 AK 3280; GDC3280; RG 6069 C19 H15 F3 N4 O2, 388.34 CAS 1799412-33-1 4H-Benzimidazol-4-one, 1,5-dihydro-1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-5-[4-(trifluoromethoxy)phenyl]- Ci8Hi4N502F3, mass 389.3 g/mol), ROCHE, Ark Biosciences , under license from Roche , is developing AK-3280, an antifibrotic agent, for the potential oral treatment of IPF. In July 2018, Ark intended to further clinical development of the drug, for IPF. …